N@N

LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) Down By 7.53% ($8.49) From $112.740 After BUYINS.NET Report Predicted Strengt

May 10, 2017 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Monday, May 8th 2017 stating that LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ) was expected to be higher After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?id=527539

  Symbol  Company                          # of Reports         Quarter  Release Time
  LGND    LIGAND PHARMACEUTICALS INCORPORATED  May Earnings         Q1       After

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

LIGAND PHARMACEUTICALS INCORPORATED (NASDAQ:LGND) - Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; CorMatrix portfolio of vascular, cardiac, and pericardial tissue repair products; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; Carnexiv that is used as replacement therapy for oral carbamazepine formulations; Nexterone, a Captisol-enabled formulation of amiodarone; Noxafil-IV, a Captisol-enabled formulation of posaconazole for IV use; Exemptia for autoimmune diseases; and Vivitra for breast cancer. The company s partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, kidney disease, and others. Its internal development program comprise products for the treatment of Type 2 diabetes mellitus, oncology, allergy, anti-coagulant, depression, sun damage, blood disorders, and diabetes. The company is also involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated has alliances, licenses, and other business relationships with various pharmaceutical companies, including Novartis AG; Amgen, Inc.; Merck & Co., Inc.; Pfizer Inc.; Celgene; Gilead Sciences; Janssen Biotech, Inc.; Baxter International, Inc.; and Eli Lilly and Company. The company was founded in 1987 and is headquartered in San Diego, California..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net